Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Alzheimer Dis Assoc Disord ; 32(3): 179-184, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29351092

RESUMO

BACKGROUND: Americans' confidence in science varies based on their political ideology. This ideological divide has potentially important effects on citizens' engagement with and participation in clinical studies of Alzheimer disease (AD). METHODS: A probability sample of 1583 Americans was surveyed about their willingness to participate in longitudinal AD research and about their political attitudes. These survey results were compared with a survey of 382 participants in a longitudinal AD study at the Knight Alzheimer Disease Research Center. RESULTS: Among Americans, more conservative ideology decreases willingness to participate in a hypothetical longitudinal cohort study of AD both directly and through its negative effect on confidence in science. The Knight Alzheimer Disease Research Center study participants expressed more liberal ideology and greater confidence in science than Americans in general. Of the survey respondents opposed to participation, over a quarter changed to neutral or positive if the study returned their research results to them. CONCLUSIONS AND RELEVANCE: Clinical studies of AD are likely biased toward participants who are more liberal and have higher confidence in science than the general population. This recruitment bias may be reduced by lowering the trust demanded of participants through measures such as returning research results to participants.


Assuntos
Doença de Alzheimer/psicologia , Ensaios Clínicos como Assunto , Conhecimento , Participação do Paciente/psicologia , Política , Revelação , Feminino , Humanos , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Ciência , Inquéritos e Questionários
2.
Alzheimers Dement ; 11(5): 533-540.e2, 2015 May.
Artigo em Inglês | MEDLINE | ID: mdl-25022536

RESUMO

BACKGROUND: Cerebrospinal fluid (CSF) proteins have become accepted biomarkers of Alzheimer's disease (AD) in research settings. The extent of their use, perceived utility, and influence on decision making in clinical settings, however, are less well studied. METHODS: Clinicians who evaluate older adults (N = 193) were randomized to view normal, borderline, AD-consistent, or no CSF information in two vignettes portraying patients with borderline and mild AD symptoms. Clinicians also reported on the use and perceived utility of CSF biomarkers. RESULTS: Although clinicians reported infrequent use and low perceived utility of CSF biomarkers, viewing AD-consistent CSF values made clinicians more likely to make an AD-related diagnosis, increased diagnostic confidence, and led clinicians to initiate treatment more often than clinicians who had no CSF information. CONCLUSIONS: CSF biomarkers influence decision making depending on the extent to which biomarkers reflect AD pathology, consistency between clinical-pathologic information, and the ambiguity of protein values.


Assuntos
Biomarcadores/líquido cefalorraquidiano , Demência/líquido cefalorraquidiano , Demência/diagnóstico , Adulto , Idoso , Peptídeos beta-Amiloides/líquido cefalorraquidiano , Feminino , Humanos , Modelos Logísticos , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Testes Neuropsicológicos , Escalas de Graduação Psiquiátrica , Distribuição Aleatória , Proteínas tau/líquido cefalorraquidiano
3.
Mov Disord ; 29(3): 405-9, 2014 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-24375511

RESUMO

BACKGROUND: We investigated the viability of psychometrically robust executive function measures as markers for premanifest Huntington's disease (HD). METHODS: Fifteen premanifest HD subjects and 42 controls were compared on the NIH EXAMINER executive function battery. This battery yields an overall executive composite score, plus working memory, cognitive control, and fluency scores that are measured on psychometrically matched scales. The scores were correlated with two disease markers, disease burden and striatal volumes, in the premanifest HD subjects. RESULTS: The premanifest HD subjects scored significantly lower on the working memory score. The executive composite positively correlated with striatal volumes, and the working memory score negatively correlated with disease burden. The cognitive control and fluency scores did not differ between the groups or correlate significantly with the disease markers. CONCLUSIONS: The NIH EXAMINER executive composite and working memory scores are sensitive markers of cognitive dysfunction, striatal volume, and disease burden in premanifest HD.


Assuntos
Transtornos Cognitivos/fisiopatologia , Função Executiva/fisiologia , Doença de Huntington/fisiopatologia , Memória de Curto Prazo/fisiologia , Adulto , Idoso , Transtornos Cognitivos/psicologia , Feminino , Humanos , Doença de Huntington/psicologia , Masculino , Pessoa de Meia-Idade , Testes Neuropsicológicos
4.
Sci Rep ; 11(1): 3120, 2021 02 04.
Artigo em Inglês | MEDLINE | ID: mdl-33542334

RESUMO

In the United States, the wide ideological divergence in public confidence in science poses a potentially significant problem for the scientific enterprise. We examine the behavioral consequences of this ideological divide for Americans' contributions to medical research. Based on a mass survey of American adults, we find that engagement in a wide range of medical research activities is a function of a latent propensity to participate. The propensity is systematically higher among liberals than among conservatives. A substantial part of this ideological divide is due to conservative Americans' lower confidence in science. These findings raise important issues for the recruitment of subjects for medical studies and the generalizability of results from such studies.


Assuntos
Pesquisa Biomédica/ética , Meios de Comunicação de Massa/ética , Moral , Participação do Paciente/psicologia , Política , Confiança/psicologia , Adulto , Escolaridade , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Inquéritos e Questionários , Estados Unidos
5.
JAMA Neurol ; 72(12): 1484-90, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26501506

RESUMO

IMPORTANCE: Results of Alzheimer disease (AD) research assessments typically are not disclosed to participants. Recent research has suggested interest in disclosure, but, to our knowledge, few studies have accounted for awareness of potential benefits and limitations of disclosure. OBJECTIVE: To determine the attitudes of cognitively normal research participants and members of the general public regarding disclosure of AD research results. DESIGN, SETTING, AND PARTICIPANTS: Participants in a longitudinal aging study (Alzheimer Disease Research Center [ADRC]) were given preintervention and postintervention surveys about disclosure attitudes. In a general public sample (The American Panel Survey), participants responded to a similar survey about disclosure attitudes. INTERVENTIONS: Participants in the ADRC sample were randomly assigned to a group (n = 119) that read an education intervention about the usefulness of AD biomarkers or to a placebo group (n = 100) that read as its intervention general information about the ADRC. Participants in the general public sample read a brief vignette describing participation in a longitudinal AD study. MAIN OUTCOME AND MEASURE: Interest in disclosure of AD research results. RESULTS: Cognitively normal ADRC participants (n = 219) were 60.7% (n = 133) female, 83.6% (n = 183) of white race, and reported a mean of 15.91 years of education. Twenty-nine individuals refused participation. The American Panel Survey participants (n = 1418) indicated they did not have AD and were 50.5% (n = 716) female, 76.7% (n = 1087) of white race, and reported a mean of 13.85 years of education. Overall, 77.6% of eligible participants (1583 of 2041) completed the survey in July 2014. Interest in disclosure was high among the ADRC participants (55.1% [119 of 216] were "extremely interested"). Viewing the education intervention predicted lower interest in disclosure (odds ratio, 2.01; 95% CI, 1.15-3.53; P = .02). High subjective risk of AD, a family history of AD, and minimal attendance at research meetings were associated with high interest after the intervention. In the general public, interest was lower overall (12.5% [174 of 1389] were "extremely interested"), but the subset of participants most likely to join an AD research study reported higher interest (43.5% [40 of 92] were extremely interested). CONCLUSIONS AND RELEVANCE: Experience with AD appears to increase interest in disclosure of AD research results. Learning about potential limitations of disclosure somewhat tempered interest. These findings should inform the development of disclosure policies for asymptomatic individuals in AD studies.


Assuntos
Doença de Alzheimer/psicologia , Atitude , Revelação , Idoso , Idoso de 80 Anos ou mais , Doença de Alzheimer/reabilitação , Feminino , Inquéritos Epidemiológicos , Humanos , Estudos Longitudinais , Masculino , Ensino/métodos
6.
Am J Alzheimers Dis Other Demen ; 28(4): 355-62, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-23687184

RESUMO

PURPOSE: We examined print advertisements for Alzheimer's disease drugs published in journals and magazines between January 2008 and February 2012, using an informational versus transformational theoretical framework to identify objective and persuasive features. METHODS: In 29 unique advertisements, we used qualitative methods to code and interpret identifying information, charts, benefit and side effect language, and persuasive appeals embedded in graphics and narratives. RESULTS: Most elements contained a mixture of informational and transformational features. Charts were used infrequently, but when they did appear the accompanying text often exaggerated the data. Benefit statements covered an array of symptoms, drug properties, and caregiver issues. Side effect statements often used positive persuasive appeals. Graphics and narrative features emphasized positive emotions and outcomes. IMPLICATIONS: We found subtle and sophisticated attempts both to educate and to persuade readers. It is important for consumers and prescribing physicians to read print advertisements critically so that they can make informed treatment choices.


Assuntos
Publicidade/métodos , Doença de Alzheimer/tratamento farmacológico , Informação de Saúde ao Consumidor/métodos , Informação de Saúde ao Consumidor/normas , Gestão da Informação em Saúde/métodos , Nootrópicos/uso terapêutico , Publicidade/normas , Idoso , Indústria Farmacêutica , Gestão da Informação em Saúde/normas , Humanos , Publicações Periódicas como Assunto , Médicos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA